OPKO Health, Inc. (OPK) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a mixed picture. Financial performance shows some decline in net income, but there's optimism in product development with potential growth in the 4Kscore product and new collaborations. Market strategy is unclear, with slow market conversion for Pfizer products. Expenses are high, impacting financial health. The shareholder return plan is not explicitly positive or negative. The Q&A reveals uncertainties in efficacy and market conversion. Overall, the rating is neutral due to balanced positives and negatives, with no strong catalysts for significant stock price movement.
Key Financial Performance
Revenue for Q3 2025 (Diagnostics business) $95.2 million, including $19.5 million from the oncology assets recently sold to Labcorp. This compares to $121.3 million in Q3 2024, with the decline primarily due to revenue attributable to the Labcorp transactions that closed in September 2024 and 2025.
4Kscore test volume Increased more than 20% in the third quarter versus the comparable year ago period. This growth is attributed to the recent FDA label expansion, allowing use of the test without the requirement of a digital rectal exam.
Total costs and expenses (Diagnostics business) $115.2 million, down from $184.2 million last year. This includes $25.2 million related to the oncology assets that were sold and approximately $4.2 million in expected nonrecurring costs for severance during the 2025 quarter.
Operating income (Diagnostics business) Improved to $81.6 million compared to $58.5 million in the third quarter of 2024. This improvement is due to gains recorded related to transactions with Labcorp and cost-saving measures.
Revenue for Q3 2025 (Pharmaceutical business) $56.4 million, up 8% or $4.1 million from 2024's $52.4 million. This increase is driven by higher revenue from Rayaldee and BARDA funding.
Rayaldee revenue $7.5 million during Q3 2025, a 29% increase from 2024's $5.8 million. This growth is primarily due to lower government rebates during the 2025 period, which offset an approximately 20% decline in volumes.
BARDA funding Increased to $8.2 million from $5.5 million, reflecting expanded activity for infectious disease antibody programs.
Pharmaceutical operating loss $24.2 million, a 25% improvement compared to last year's operating loss of $32.2 million. This improvement is attributed to cost containment activities and increased R&D investment.
Consolidated operating income $48.1 million, improved from 2024's $14.2 million as a result of improved results at BioReference and gains from the disposition of assets.
Net income in Q3 2025 $21.6 million or $0.03 per basic and diluted share compared to $24.9 million or $0.04 per basic share and $0.03 per diluted share in Q3 2024. The 2024 period benefited from gains on certain underlying investments.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
ModeX's MSTAR platform: Entered into a research collaboration and license agreement with Regeneron to develop multispecific antibodies for various indications.
MDX2004: A multispecific immune rejuvenator entered Phase I clinical trials last month.
MDX2001: Advanced to its fifth cycle of escalation in Phase I trials with acceptable safety and tolerability.
EBV vaccine: In partnership with Merck, advanced to Phase I human trials for immunogenicity, safety, and tolerability evaluation.
MDX2003: A tetraspecific T cell engager for B-cell leukemia and lymphoma expected to enter the clinic early next year.
MDX2301: A bispecific tetravalent antibody for COVID infections, funded by BARDA, expected to begin Phase I studies early next year.
OPK-88006: A treatment for MASH and obesity, with subcutaneous formulation entering the clinic in early 2026 and oral formulation later that year.
4Kscore test: FDA label expansion allows use without a digital rectal exam, opening a significant new market of primary care physicians.
BioReference Health: Streamlined operations focusing on core clinical testing in New York and New Jersey, with a 5.3% increase in testing volume in Q3.
International operations: Steady sales growth and meaningful cash flow from OPKO Health Iberoamerica and EirGen Pharma.
Sale of BioReference Health's oncology division: Generated $192.5 million at closing and $32.5 million in performance-based earn-out, streamlining lab business for profitable growth.
Stock repurchase program: Repurchased $25.1 million worth of stock in 2025, with $126 million remaining under the program.
Operational efficiencies at BioReference: Employee headcount reduced by 25% since January, improving margins and positioning for sustained growth.
Collaboration with Regeneron: Potential milestone payments exceeding $1 billion and tiered royalties up to low double digits on global net sales.
BARDA collaboration: Advancing multispecific antibodies for COVID and influenza with $22 million in non-dilutive funding received so far.
Focus on profitability: BioReference poised for profitability and growth, with a clear path to cash flow positive operations.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory and Clinical Trial Risks: The company is advancing multiple clinical trials, including MDX2001, MDX2004, and MDX2003, as well as a COVID antibody program funded by BARDA. These trials are subject to regulatory review and approval, which could delay or halt progress. Additionally, the success of these trials is uncertain, and failure could impact the company's pipeline and financials.
Market and Competitive Pressures: The company faces competitive pressures in the diagnostics and pharmaceutical sectors, particularly in the adoption of its 4Kscore test and other innovative therapeutics. The success of these products depends on market acceptance and the ability to differentiate from competitors.
Operational Efficiency and Cost Management: While the company has implemented cost-saving measures, including a 25% reduction in BioReference employee headcount, there is a risk that these measures may not achieve the desired profitability or could impact operational efficiency.
Economic and Currency Risks: The company’s international operations face foreign currency pressures, particularly in Latin America, which could impact revenue and profitability.
Dependence on Partnerships and Funding: The company relies on partnerships, such as those with Regeneron, Merck, and BARDA, for funding and development. Any changes in these partnerships or failure to meet milestones could adversely affect the company’s financials and strategic objectives.
Product Development and Commercialization Risks: The development of new products, such as OPK-88006 for MASH and obesity, and the oral GLP-2 tablet for short bowel syndrome, involves significant investment and uncertainty. Delays or failures in development or commercialization could impact revenue growth.
Revenue Concentration and Asset Divestitures: The sale of BioReference Health's oncology division and reliance on remaining assets for profitability pose risks if the streamlined operations fail to achieve expected growth and revenue targets.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance for Q4 2025: Total revenue is expected to be between $135 million to $140 million, with revenue from services of $70 million to $75 million, revenue from products of $40 million to $45 million, and other revenue of $25 million to $30 million. This includes Pfizer profit share of $10 million to $12 million and BARDA revenue of $7 million to $9 million.
Cost and Expense Guidance for Q4 2025: Total costs and expenses are expected to be between $175 million and $180 million, excluding any nonrecurring or restructuring costs. Research and development expense is expected to be between $30 million and $35 million, offset partially by BARDA revenue. Depreciation and amortization expense is expected to be approximately $24 million.
2026 Revenue and Profitability Outlook: BioReference is expected to be profitable and grow revenue in the low single-digit percentages. In-line pharmaceutical businesses, including Rayaldee, are expected to grow in the mid-single-digit percentages and improve operating income by low double-digit percentages. NGENLA profit share payments are expected to increase to approximately $32 million to $35 million.
2026 R&D Investment: The company plans to invest up to $100 million in R&D programs, net of any partnering reimbursement, with up to 6 Phase I programs enrolling patients during 2026.
BioReference Growth and Profitability: Following the oncology transaction, BioReference is expected to achieve cash flow positive and profitable growth, excluding any nonrecurring or noncash items.
Pharmaceutical Segment Growth: Rayaldee is expected to grow in the mid-single-digit percentages, with improved operating income by low double-digit percentages.
BARDA Funding and Programs: BARDA revenue is expected to be $7 million to $9 million in Q4 2025. The company continues to advance multispecific antibody protein candidates for COVID and influenza, with Phase I clinical trials expected to commence early next year.
Clinical Trials and Product Development: The company anticipates entering the clinic with OPK-88006 for MASH and obesity in early 2026 for subcutaneous formulation, with the oral formulation to follow later that year. Additionally, Phase I studies for MDX2301 (COVID antibody) and MDX2003 (lymphoma and leukemia treatment) are expected to begin early next year.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Stock Repurchase Program: OPKO Health is devoting a portion of the proceeds from the sale of BioReference Health's oncology division to its stock repurchase program. During 2025, the company repurchased $25.1 million worth of stock. As of September 30, 2025, $126 million remained under this program.
Share Buyback Activity: In the third quarter of 2025, OPKO Health repurchased 11.1 million shares. For the full year, nearly 25 million shares were repurchased for approximately $33.5 million. The company has $126 million remaining authorized under its buyback program and plans to continue repurchasing shares throughout the year.
Capital Allocation for Shareholder Returns: OPKO Health has deployed nearly $100 million in 2025 for convertible note repurchases and conversions, as well as common stock repurchases. Since the start of 2024, over $215 million has been allocated to these activities, demonstrating a commitment to returning capital to shareholders.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:How many patients have been dosed at the fifth dose level for MDX2001, and will the program proceed to dose level 6?
A:Five patients have been dosed at the fifth dose level, and the program is expected to proceed to dose level 6 after the suitable observation period is complete. The total number of patients exposed to the treatment is close to 30.
Q:Can you share more about the safety profile and efficacy signals of MDX2001?
A:Management stated it is too early to comment on efficacy as responses with a small number of patients are anecdotal. They plan to evaluate efficacy during the Phase Ib expansion cohorts.
Q:What is the growth outlook for the 4Kscore product, and is it related to the label expansion?
A:The 20% growth mentioned is based on the former label, not the recent label expansion. The new label expands the market to primary care doctors, and management expects significant growth over time.
Q:Can you provide more granularity on tracking the progress of the 4Kscore product?
A:Management agreed to provide more granularity on tracking progress in the future.
Q:What is the scope of the Regeneron collaboration, and how many programs are ongoing?
A:The collaboration is not exclusive to oncology and includes four programs covering metabolism, oncology, and immunology. The agreement allows for expansion if new opportunities arise.
Q:Do the milestone payments in the Regeneron collaboration include preclinical and clinical milestones?
A:Yes, the milestone payments include both preclinical and clinical milestones. Regeneron will reimburse preclinical costs, and there are milestones for progression to Phase I and beyond.
Q:What is the patient selection strategy for the Phase Ib expansion cohorts of MDX2001?
A:Patient selection will focus on tumor types with high levels of CMet and Trop2 expression and those likely to respond to immune therapies, such as non-small cell lung cancer, renal cell carcinoma, and PD-1 failures in melanoma.
Q:What is the guidance for the diagnostic service business profitability and gross margins?
A:Gross margins are expected to be in the mid-20s in Q4, increasing to the high 20s to low 30s in the first half of next year.
Q:Are there updates on partnerships in infectious diseases beyond the EBV deal with Merck?
A:Yes, ModeX is working on infectious disease targets like flu, HIV, and hepatitis B. They are also exploring MDX2004 as an immune rejuvenator for various infections and chronic diseases.
Q:What are the potential indications for MDX2004, and could it be combined with other cancer assets?
A:Potential indications include hepatitis B, chronic infections in diabetics, and chronic HIV. MDX2004 could potentially be combined with other cancer assets, such as PD-1s or CAR T cells.
Q:Will the EBV vaccine Phase I data be reported, and will the public be informed about Phase II?
A:Merck is expected to report Phase I data at the appropriate time. The public will be informed when the program progresses to Phase II.
Q:What is the rationale for targeting CD19 and CD20 together in a product?
A:Targeting both CD19 and CD20 helps prevent or delay the emergence of resistant variants, as tumors may downregulate one antigen and promote the outgrowth of the other after treatment.
Q:What is the severance cost related to the asset sale, and is it separate from other expenses?
A:The severance cost is $4.2 million and is separate from the $25.2 million of costs and expenses associated with the asset sale.
Q:What is the volume growth and pricing assumption for the diagnostic lab business in 2026?
A:Volume growth is expected to be in the low single digits, with stable pricing. There is potential upside for reimbursement related to 4Kscore.
Q:Why is the Pfizer profit share guidance for 2026 lower than expected?
A:The market for long-acting treatments is converting slower than expected, and daily patients are not converting as quickly. Pfizer holds about one-third of the global long-acting market.
Q:Is the revenue growth for 4Kscore aligned with the 20% test volume growth?
A:Yes, revenue growth is similar to the 20% test volume growth.
Q:Review of Unclear Management Responses
A:Management avoided providing direct answers or clarity on the following: 1. Efficacy signals for MDX2001, stating it is too early to comment. 2. Specific revenue figures for 4Kscore, despite being asked for year-to-date or quarterly data. 3. Detailed timelines for the EBV vaccine Phase II start, leaving it to Merck's discretion. 4. Specifics on the Pfizer profit share guidance, only attributing it to slower market conversion without detailed data.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
BioReference profitability
ESMO
Health oncology
Jersey region
MASH obesity
MDX cell
MDX class
MSTAR platform
ModeX
Regeneron binder
Therapeutics segment
agreement Regeneron
cell engager
class multispecific
cohort
development process
direction
exam
expansion
immunogenicity
impairment
indication interest
infection
influenza
license
medicine
milestone
multispecific antibody
platform Regeneron
program clinic
protection
rejuvenator
safety tolerability
stage program
starting dose
strain
OPK Transcript
OPKO Health, Inc. (OPK) Q1 2026 Earnings Call Transcript
Unknown4-28
The earnings call summary reveals a decline in revenue and gross margin, alongside an increased net loss and operating expenses, which are negative indicators. The Q&A session did not provide additional insights or alleviate concerns. The lack of discussion on operational updates, strategic initiatives, and shareholder returns further contributes to uncertainty. Hence, the sentiment is negative, anticipating a stock price decline of -2% to -8% over the next two weeks.
OPKO Health, Inc. (OPK) Q4 2025 Earnings Call Transcript
Unknown2-26
The earnings call highlights a decline in revenue and increased losses, despite some growth in specific segments like the 4Kscore test. The Q&A section reveals uncertainties around key projects and a lack of detailed timelines for critical milestones. Although there's a commitment to shareholder returns through repurchases, the overall financial health and guidance adjustments suggest a negative sentiment, potentially leading to a stock price decrease.
OPKO Health, Inc. (OPK) Q3 2025 Earnings Call Transcript
Unknown10-29
The earnings call presents a mixed picture. Financial performance shows some decline in net income, but there's optimism in product development with potential growth in the 4Kscore product and new collaborations. Market strategy is unclear, with slow market conversion for Pfizer products. Expenses are high, impacting financial health. The shareholder return plan is not explicitly positive or negative. The Q&A reveals uncertainties in efficacy and market conversion. Overall, the rating is neutral due to balanced positives and negatives, with no strong catalysts for significant stock price movement.
OPKO Health, Inc. (OPK) Q2 2025 Earnings Call Transcript
Positive7-31
The earnings call shows positive developments: a strategic sale to Labcorp, promising product development, and cost reduction initiatives. The Q&A highlights growth in NGENLA prescriptions, 4Kscore test sales, and potential for oxyntomodulin in obesity/MASH treatment. The share repurchase program and cash flow positive guidance further boost sentiment. Despite some management ambiguity, the overall outlook is positive, with optimistic guidance and strategic initiatives likely to drive a stock price increase in the short term.
OPK Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
